Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inamed v. Ethicon Endo-Surgery

This article was originally published in The Gray Sheet

Executive Summary

Trial date for Inamed's royalty dispute with Dr. Lubomyr Kuzmak and Johnson & Johnson/Ethicon Endo-Surgery, regarding patents related to Inamed's LapBand gastric band obesity device,will be set by September. The trial will probably begin by the end of the year, according to Inamed. On June 18, a Los Angeles federal court ruled that a January 2000 settlement, establishing a licensing agreement between Inamed and Kuzmak, was unenforceable. While the original patent suit will move forward, Inamed hopes the settlement can be restored following an appeal of the June 18 decision...

You may also be interested in...



Ethicon/Obtech

Johnson & Johnson's Ethicon Endo-Surgery unit gains Swedish Adjustable Gastric Band laparoscopic surgical device for treatment of morbid obesity through June 27 purchase of Obtech Medical AG. The SAGB system has been available in Europe since 1987, but U.S. commercialization plans have not been finalized. Ethicon owns patents originally held by Lubomyr Kuzmak, MD, related to gastric band technology similar to the SAGB, but they are the subject of infringement litigation by Lap-Band maker Inamed (1"The Gray Sheet" June 24, 2002, In Brief)...

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016769

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel